Latest News

Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.

Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.

Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.

Noab Banoub, a third year medical student, describes his journey into medicine and his view of ophthalmology's future.

At AAO 2026, Adam, MD, shares Yamane technique pearls, from docking the trailing haptic to preventing tilt and haptic exposure.

Uveitis is uncommon, but it causes a disproportionate share of visual morbidity.

Discover how IRIS Registry real-world data turns EHR notes and images into evidence that speeds ophthalmology trials, recruitment, safety studies, and post-approval insights.

FDA accepts vamikibart BLA for UME as data show sustained gains at 1 year; decision July 2027.

FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.

Anti-VEGF for ROP is not associated with systemic and neurodevelopmental outcomes.

The evidence for nutrition in eye care is strong for some conditions and thin or absent for others.

A successful premium outcome depends not only on the lens, but also on how well the patient understands what to expect before surgery.

Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual effects.